Immunological response to bolus versus multiple injections of hylan G‐F 20 (Synvisc®) in a murine biocompatibility model. Issue 7 (6th February 2014)

• Record Type: Journal Article
• Authors: Markel, David C.; Jackson, Nancy M.; Esquivel, Amanda O.; Ren, Weiping; Flynn, Jeffrey C.
• Is Part Of: Journal of biomedical materials research. Volume 102:Issue 7(2014:Oct.)
• Page Start: 1375
• Page End: 1380
• Publication Date: 2014-02-06
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.b.33116
• Languages: English
• ISSNs: 1552-4973

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <p>Local tissue reactivity to intra‐articular injections of hyaluronic acid hylan G‐F 20 (Synvisc<sup>®</sup>) has been described. We used a murine biocompatibility model to study the inflammatory response to Synvisc<sup>®</sup> after a single bolus injection versus the traditional three shot series of injections. Air pouches were established subcutaneously in BALB/c mice, which were injected with phosphate‐buffered saline (PBS), 5 mg ultra‐high molecular weight polyethylene particles (to simulate synthetic joint wear debris, positive control), 0.5 mL Synvisc<sup>®</sup> (one injection/week for three weeks, harvested 14 days after last injection), or 1.5 mL Synvisc<sup>®</sup> bolus (harvested either 14 or 28 days after last injection). Inflammatory gene expression and inflammation of air pouch tissue, and serum antibody titers to Synvisc<sup>®</sup> were determined. Inflammation was observed with all Synvisc<sup>®</sup> treatments relative to PBS (<italic>p</italic> < 0.01). However, the three injection series of Synvisc<sup>®</sup> resulted in significantly (<italic>p</italic> < 0.05) greater tumor necrosis factor‐alpha gene expression compared to both PBS and bolus single shot Synvisc<sup>®</sup> harvested after 14 or 28 days. While all Synvisc<sup>®</sup> treatments resulted in serum antibodies to Synvisc<sup>®</sup> (<italic>p</italic> < 0.02 compared to PBS control group), mice that received three injections of Synvisc<sup>®</sup> had higher levels than mice receiving a single injection (<italic>p</italic> < 0.01). These results demonstrate that a single bolus injection of Synvisc<sup>®</sup> led to less inflammation and a lower antibody response when compared to the three‐shot series of injections, supporting the current change in treatment from multiple injections to a single injection of Synvisc<sup>®</sup>. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 102B: 1375–1380, 2014.</p> </abstract>